The 1+3 bill passed a plenary session of the National Assembly's Health and Welfare Committee on the morning of the 16th and will be reviewed by the legislation and judiciary committee.

The resolution reflected the revision of the supplementary provision, which excludes the report from the MFDS within a month from the enforcement date of the law, a drug for data-based re-evaluation, which was approved before the enforcement of the law. The welfare committee has passed on a number of the pharmaceutical affairs law to the judiciary committee, including the bill, mandatory preparation and submission of expenditure reports on pharmaceutical CSO, designation of drug days as a legal anniversary, and mandatory